Latest News
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
November 12, 2025
ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
ANDA application for Risperidone extended-release injectable suspension managed by CBCC has received Marketing Authorization from the USFDA!
Type of Application: 505 (j)
Therapeutic Area: Psychiatry
Scope: End-to-end clinical trial management
Country of Trial Execution: India
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Sanjeev Ganatra Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas
ClinicalResearch PharmaceuticalScience DrugDevelopment
ClinicalTrials PhaseITrial MedicalResearch
